Harpreet Dhindsa
Nephrology · Fresno, CANPI 1801864020
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 154 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 25 manufacturers reported payments, led by Amgen at 26.7% of the total. Reporting peaked in 2024 at $1,224 and has fallen 65.9% since, to $417 in 2025.
Across 154 payments — averaging $19.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$812
- AstraZeneca$405
- Kerecis Limited$280
- Travere Therapeutics, Inc.$259
- Mallinckrodt Hospital Products Inc.$207
- Otsuka America Pharmaceutical, Inc.$170
- plus $912 from 19 others
Across 49 payments — averaging $528.49 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Calliditas Therapeutics US Inc.$13K
- Akebia Therapeutics Inc$7K
- CSL Behring$6K
What the payments were for
- Food & beverage$3,045100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen(2 entities) | 47 | $812 |
| AstraZeneca | 24 | $405 |
| Kerecis Limited | 1 | $280 |
| Travere Therapeutics, Inc. | 13 | $259 |
| Mallinckrodt Hospital Products Inc. | 11 | $207 |
| Otsuka America Pharmaceutical, Inc. | 8 | $170 |
| Aurinia Pharma U.S., Inc. | 8 | $166 |
| GSK | 9 | $166 |
| Bayer | 8 | $134 |
| Calliditas Therapeutics US Inc. | 4 | $72 |
| Akebia Therapeutics Inc | 2 | $45 |
| Daiichi Sankyo Inc. | 2 | $41 |
| Fresenius USA Marketing, Inc. | 3 | $41 |
| Scpharmaceuticals Inc. | 2 | $32 |
| Novartis | 2 | $30 |
| Kyowa Kirin, Inc. | 1 | $28 |
| Shire North American Group Inc | 1 | $25 |
| Abbott | 1 | $21 |
| Argon Medical Devices, Inc. | 1 | $21 |
| ANI Pharmaceuticals, Inc. | 1 | $20 |
| Ultragenyx Pharmaceutical Inc. | 1 | $17 |
| Lilly USA, LLC | 1 | $15 |
| Sanofi | 1 | $14 |
| Boehringer Ingelheim | 1 | $13 |
| Genentech USA, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,045 in reported general payments places this provider in the 70th percentile of 1,341 nephrology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FilspariSparsentan | 16 | $180,662 |
| FarxigaDapagliflozin Propanediol | 84 | $101,556 |
| VeltassaPatiromer Calcium Sorbitex | 48 | $82,428 |
| KerendiaFinerenone | 57 | $80,085 |
| VelphoroSucroferric Oxyhydroxide | 15 | $51,550 |
| Sevelamer Carbonate | 91 | $25,690 |
| ProsolParenteral Amino Acid 20% No.1 | 88 | $21,813 |
| LokelmaSodium Zirconium Cyclosilicate | 17 | $19,951 |
| AuryxiaFerric Citrate | 15 | $15,751 |
| JardianceEmpagliflozin | 12 | $10,907 |
| Calcium Acetate | 65 | $6,248 |
| Hydralazine Hcl | 154 | $2,305 |
| Midodrine Hcl | 36 | $2,140 |
| Nifedipine ErNifedipine | 39 | $1,915 |
| Calcitriol | 119 | $1,651 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Travere Therapeutics, Inc.Filspari | $259 | $180,66216 claims |
| AstraZenecaFarxiga, Lokelma | $405 | $121,507101 claims |
| BayerKerendia | $134 | $80,08557 claims |
| Fresenius USA Marketing, Inc.Velphoro | $41 | $51,55015 claims |
| Akebia Therapeutics IncAuryxia | $45 | $15,75115 claims |
| Boehringer IngelheimJardiance | $13 | $10,90712 claims |
| ANI Pharmaceuticals, Inc.Valsartan | $20 | $45318 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 1,341 nephrology providers in California.
Other nephrology in Fresno
- Anjay RastogiLos Angeles$2.2M
- Glenn ChertowStanford$2M
- Luis AlvarezPalo Alto$1.8M
- Jose MorfinSacramento$1M
- Rodolfo BatarseRancho Mirage$910K
- Vandana MathurWoodside$769K
- Yasir QaziOrange$618K
- Rafael VillicanaLoma Linda$610K
- Sunil PatelApple Valley$509K
- Suphamai BunnapradistLos Angeles$498K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.